Definitions

from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A drug that acts as a Gardos channel blocker.

Etymologies

Sorry, no etymologies found.

Examples

  • This decrease in operating expenses was primarily due to decreased research and development costs as a result of the Company's decision to terminate the development of senicapoc for asthma, as well as decreased operating expenses resulting from the Company's ongoing cost reduction efforts.

    News

  • These decreases were partially offset by an increase in expenses related to the development of senicapoc for asthma and a restructuring charge incurred as a result of a limited reduction in the workforce during the year.

    News

  • The decrease in operating expenses for the third quarter of 2010, as compared to the same period in 2009, was primarily due to a reduction in expenses related to the development of senicapoc for asthma, which has been discontinued.

    Icagen Reports Third Quarter 2010 Financial Results and Operational Highlights - Yahoo! Finance

  • Approximately 30 patients at two research centers in the United Kingdom were randomized in a 1: 1 ratio to senicapoc or placebo.

    News

  • "With its novel mechanism of action, senicapoc represents a potential new oral therapy for asthma patients, and we look forward to having the results of this trial, which we expect to be available later this year."

    News

  • As previously reported, the allergen challenge trial is a double-blind, placebo-controlled, parallel group study that is designed to assess the safety and efficacy of senicapoc administered orally on pulmonary function in patients with allergic asthma following exposure to a known antigen.

    News

  • "We are very pleased to have achieved another important milestone in the development of senicapoc for asthma," stated Seth V. Hetherington, M.D.,

    News

  • Two separate Phase II proof-of-concept clinical trials of senicapoc as a treatment for asthma are currently ongoing, one focused on allergic asthma and the second focused on exercise-induced asthma.

    News

  • Results from preclinical studies demonstrated the ability of senicapoc to reverse antigen-induced increases in airway resistance and airway hyper-reactivity.

    News

  • (Nasdaq: ICGN) today reported the completion of enrollment in the Company's Phase II proof-of-concept study of senicapoc in patients with allergic asthma.

    News

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.